Literature DB >> 12953148

Usefulness of technetium-99m hexamethylpropylene amine oxime lung scan to detect subclinical lung injury in patients with chronic renal failure.

C-H Chang1, H-C Wu, J-J P Tsai, C-C Lin, C-C Lee, A Kao.   

Abstract

We used technetium-99m hexamethylpropylene amine oxime (Tc-99m HMPAO) lung scan to detect subclinical lung injury in patients with chronic renal failure (CRF), on regular hemodialysis (HD), who had normal chest X-ray findings (CXR) and pulmonary function test (PFT). The degree of pulmonary vascular endothelium damage was represented as lung/liver uptake ratios (L/L ratios) calculated by Tc-99m HMPAO lung scan. The L/L ratios of the 20 male CRF patients on HD with normal CXR and PFT were compared with those of the 20 male normal controls. The results show that the L/L ratios on Tc-99m HMPAO lung scans were significantly higher in CRF patients on HD (1.06 +/- 0.55) than those in normal controls (0.34 +/- 0.09). Using a cut-off value of 0.50, 18/20 [90%] CRF patients had abnormally increased L/L ratios. Our findings concluded that the pulmonary vascular endothelium damage represented as significantly increased L/L ratios on Tc-99m HMPAO lung scan in CRF patients on HD with normal CXR and PFT. In addition, Tc-99m HMPAO lung scan has the potential to be a sensitive, objective and noninvasive method to detect subclinical lung injury of CRF patients on HD, which is different from the traditional studies such as CXR or PFT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12953148     DOI: 10.1007/s00408-003-1010-5

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  8 in total

1.  The in vivo distribution of 99Tcm-HM-PAO in normal man.

Authors:  D C Costa; P J Ell; I D Cullum; P H Jarritt
Journal:  Nucl Med Commun       Date:  1986-09       Impact factor: 1.690

2.  Changes in lung capillary permeability in renal failure.

Authors:  W A Crosbie; S Snowden; V Parsons
Journal:  Br Med J       Date:  1972-11-18

3.  Increased lung uptake of technetium-99m hexamethylpropylene amine oxime in systemic lupus erythematosus.

Authors:  C-M Shih; Y-C Shiau; J J Wang; S-T Ho; A Kao
Journal:  Respiration       Date:  2002       Impact factor: 3.580

4.  Ultrastructural observations of chronic uremic lungs with special reference to histochemical and X-ray microanalytic studies on altered alveolocapillary basement membranes.

Authors:  Y S Lee
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

5.  Tc-99m HMPAO diffuse pulmonary uptake demonstrated in cigarette smokers.

Authors:  W J Shih; F Gruenwald; H J Biersack; R Berger; S Brandenburg; J Coupal; U Y Ryo
Journal:  Clin Nucl Med       Date:  1991-09       Impact factor: 7.794

6.  Lung 99mTc DTPA transfer in renal disease and pulmonary infection.

Authors:  M J O'Doherty; D Breen; C Page; I Barton; T O Nunan
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

7.  Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking.

Authors:  G R Mason; J M Uszler; R M Effros; E Reid
Journal:  Chest       Date:  1983-01       Impact factor: 9.410

8.  Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies.

Authors:  P F Sharp; F W Smith; H G Gemmell; D Lyall; N T Evans; D Gvozdanovic; J Davidson; D A Tyrrell; R D Pickett; R D Neirinckx
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

  8 in total
  2 in total

1.  Technetium-99m hexamethylpropylene amine oxime lung scintigraphy findings in low-dose amiodarone therapy.

Authors:  G Capa Kaya; T Ertay; B Tuna; R Bekis; C Tasci; E Sayit; O Yilmaz; A Kargi; H Durak
Journal:  Lung       Date:  2006 Mar-Apr       Impact factor: 2.584

2.  Assessment of lung toxicity caused by bleomycin and amiodarone by Tc-99m HMPAO lung scintigraphy in rats.

Authors:  G Gumuser; K Vural; T Varol; Y Parlak; I Tuglu; G Topal; E Sayit
Journal:  Ann Nucl Med       Date:  2013-04-05       Impact factor: 2.668

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.